PIK3CA and neoplasm: Finally, genetic alterations such as ERBB2 amplification and functionally relevant mutations in oncogenes and tumor suppressor genes were found in 35.0 and 60.0% of patients, respectively, which is in accordance with the literature.12 This may cause ADT resistance by activating other tumor‐driving pathways, such as the PI3K‐AKT pathway, in the presence of an active AR pathway.